Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pozelimab · Veopoz, REGN-3918

Monoclonal antibody · Inhibitor of complement C5 (C5) · developed by Regeneron Pharmaceuticals

Approved FDA, Aug 2023
REGN Developer
1 Registered trials

What is Pozelimab?

Pozelimab is a human IgG4 monoclonal antibody that binds the terminal complement protein C5, blocking its cleavage into C5a and C5b and thereby preventing membrane-attack complex formation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Veopoz, REGN-3918
Drug type
Monoclonal antibody
Targets
complement C5 (C5)
Mechanism
Inhibitor of complement C5 (C5)
Pathways
terminal complement activation, membrane-attack complex (C5b-C9) formation
Therapy area
Hematology
Developer
Regeneron Pharmaceuticals (REGN)
FDA status
Approved as Veopoz (August 18, 2023), BLA761339 · FDA label
UNII
0JJ21K6L2I

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 4, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06541704 Phase 3 Age-related Macular Degeneration (AMD) Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Paroxysmal Nocturnal Hemoglobinuria

Other drugs acting on C5

More from Regeneron Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Pozelimab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.